Search results
Results from the WOW.Com Content Network
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
Estradiol valerate/cyproterone acetate (EV/CPA), sold under the brand names Climen and Femilar among others, is a combination product of estradiol valerate (EV), an estrogen, and cyproterone acetate (CPA), a progestogen, which is used in menopausal hormone therapy and as a birth control pill to prevent pregnancy. [1] It is taken by mouth. [1]
Co-cyprindiol, a shortened form of combination of cyproterone acetate and ethinylestradiol, is a generic name of EE/CPA. [ 25 ] [ 26 ] [ 27 ] It is also known by its former developmental code names SHB 209 AB (Diane) [ 28 ] [ 21 ] [ 29 ] and SHB 209 AE (Diane-35).
Testosterone levels with different doses of cyproterone acetate (CPA), segesterone acetate (SGA), norethisterone acetate (NETA), and levonorgestrel (LNG) alone then in combination with transdermal testosterone followed by discontinuation and recovery in healthy young men. [156] Levels decreased by about 65% with cyproterone acetate alone. [156]
Estradiol valerate and cyproterone acetate (brand name Femilar) – introduced in Finland (only) in 1993 [3] Estradiol valerate and dienogest (brand names Qlaira, Natazia) – introduced in Europe in 2009 and the U.S. Tooltip United States in 2010 [4] Estradiol and nomegestrol acetate (brand name Zoely) – introduced in Europe in 2011 [5]
Cyproterone, also known by its developmental code name SH-80881, is a steroidal antiandrogen which was studied in the 1960s and 1970s but was never introduced for medical use. [ 1 ] [ 2 ] [ 3 ] It is a precursor of cyproterone acetate (CPA), an antiandrogen, progestin , and antigonadotropin which was introduced instead of cyproterone and is ...
Cyproterone acetate was developed to overcome this problem. It is formed by adding an acetate group to cyproterone, see figure 3. Cyproterone acetate has a dual mode of action as it competes directly with DHT for binding to AR, but also inhibits gonadotropin secretion. It thereby reduces androgen, estrogen and LH levels.
Unlike antigonadotropic antiandrogens like cyproterone acetate and GnRH analogues, bicalutamide does not suppress production of testosterone or estradiol and instead actually increases it [citation needed], which has an important involvement in the differential side-effect profiles of the medications. [citation needed]